EMA To Revisit Rejection Of Elzonris & Gamifant
Executive Summary
A much slimmed-down August agenda for the European Medicines Agency’s drug assessment body, the CHMP, also shows that Janssen has asked for more time to reply to questions about its potential multiple sclerosis therapy, ponesimod.